This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arnold, A. M. Articles by Shepherd, F. Search for Related Content PubMed PubMed Citation Articles by Arnold, A. M. Articles by Shepherd, F. Related Articles Related Correspondence Social Bookmarking                            What's this?

Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

Andrew M. Arnold, Lesley Seymour, Michael Smylie, Keyue Ding, Yee Ung, Brian Findlay, Christopher W. Lee, Marina Djurfeldt, Marlo Whitehead, Peter Ellis, Glenwood Goss, Adrien Chan, Jacinta Meharchand, Yasmin Alam, Richard Gregg, Charles Butts, Peter Langmuir, Frances Shepherd

From the National Cancer Institute of Canada–Clinical Trials Group, Kingston, Ontario, Canada; and AstraZeneca, Wilmington, DE

Address reprint requests to Lesley Seymour, MD, PhD, NCI-Canada Clinical Trials Group, 10 Stuart St, Kingston, K7L3N6, ON, Canada; e-mail: lseymour{at}ctg.queensu.ca

Purpose This double-blind randomized phase II trial examined whether vandetanib, an inhibitor of vascular endothelial and epidermal growth factor receptors, could prolong progression-free survival in responding patients with small-cell lung cancer.

Patients and Methods Eligible patients with complete response (CR) or partial response (PR) to combination chemotherapy (± thoracic or prophylactic cranial radiation) received oral vandetanib 300 mg/d or matched placebo. With 100 patients and 77 events, the study had 80% power to detect an improvement in median progression-free survival from 4 to 6.5 months (one-sided, 10%-level test).

Results Between May 2003 and March 2006, 107 patients were accrued; 46 had limited disease and 61 extensive disease. There were fewer patients with a performance status of 0 (n = 11 v 20), and fewer had CR to initial therapy (n = 4 v 8) in the vandetanib arm. Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash. Asymptomatic Corrected QT interval (QT_C) prolongation was observed in eight vandetanib patients. Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51). Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9). In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).

Conclusion Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.

Supported in part by a grant to the National Cancer Institute of Canada–Clinical Trials Group from AstraZeneca Ltd, and in part by grants from the National Cancer Institute of Canada and the Canadian Cancer Society.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• The Debate About Maintenance Is Not Over in Small-Cell Lung Cancer
  Mehmet Artac and Hakan Bozcuk
  JCO 2007 25: 5840 [Full Text]

This article has been cited by other articles:

				Y. J. Lee, A. Cho, B. C. Cho, M. Yun, S. K. Kim, J. Chang, J. W. Moon, I. K. Park, H. J. Choi, and J.-H. Kim High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2426 - 2432. [Abstract] [Full Text] [PDF]

				A. Morabito, M. C. Piccirillo, F. Falasconi, G. De Feo, A. Del Giudice, J. Bryce, M. Di Maio, E. De Maio, N. Normanno, and F. Perrone Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions Oncologist, April 1, 2009; 14(4): 378 - 390. [Abstract] [Full Text] [PDF]

				L. M. Krug and M. C. Pietanza Emerging Therapies in Small Cell Lung Cancer ASCO Educational Book, January 1, 2009; 2009(1): 455 - 460. [Abstract] [Full Text] [PDF]

				T. Sher, G. K. Dy, and A. A. Adjei Small Cell Lung Cancer Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr., E. B. Haura, and J. V. Heymach Emerging Therapies for Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): e5 - e14. [Abstract] [Full Text] [PDF]

				B. E. Johnson, C. M. Rudin, and R. Salgia Novel and Targeted Agents for Small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 363 - 367. [Abstract] [Full Text] [PDF]

				M. Artac and H. Bozcuk The Debate About Maintenance Is Not Over in Small-Cell Lung Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5840 - 5840. [Full Text] [PDF]

				L. Seymour and on behalf of the BR.20 study team In Reply: J. Clin. Oncol., December 20, 2007; 25(36): 5840 - 5841. [Full Text] [PDF]